Anti-CD19 CAR-T cell therapy and anti-CD19 monoclonal antibody therapies have already demonstrated efficacy in treating hematologic cancers, and more recently, CD19-targeted CAR-T cell therapy has been extended to autoimmune diseases[14,15]. The gene discussed is CD19; the disease is hematopoietic and lymphoid cell neoplasm.